Skip to main content
. Author manuscript; available in PMC: 2012 Oct 1.
Published in final edited form as: Mol Cancer Ther. 2011 Aug 4;10(10):1774–1783. doi: 10.1158/1535-7163.MCT-11-0304

Figure 6. Baicalein inhibits cancer cell growth in vivo.

Figure 6

A, Baicalein suppresses growth of xenogeneic AGS tumors. AGS cells were implanted and treatment started as indicated on d7 as described in Methods. The x-axis represents weeks after AGS implantation. *p=0.03 for baicalein versus carrier or genistein; **p=0.006 for baicalein versus carrier. n=6–7/group. Error bars are SEM. B, Baicalein enhances IRF-1 activity in mouse C3L5 cells by luciferase reporter assay. C3L5 cells were treated with baicalein, and transient luciferase reporter assay was performed as described in Supplemental Methods. C, MTT assay of C3L5 cells treated with baicalein. Cell viability was determined by MTT assay at 72h post treatment as indicated. D, Intraperitoneal baicalein suppresses growth of syngeneic C3L5 tumors in C3H/HeJ female mice. Treatment was initiated on d5 after C3L5 implantation, when tumors were palpable, as described in Methods. n=5–6/group. *p=0.01, **p=0.001 versus control.